A week ago, 10x Genomics, Inc. (NASDAQ:TXG) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. Revenues and losses per share were both better than expected, with revenues of US$151m leading estimates by 3.0%. Statutory losses were smaller than the analystsexpected, coming in at US$0.14 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

Following last week's earnings report, 10x Genomics' 15 analysts are forecasting 2026 revenues to be US$619.4m, approximately in line with the last 12 months. Losses are forecast to balloon 24% to US$0.72 per share. Before this earnings announcement, the analysts had been modelling revenues of US$614.1m and losses of US$0.81 per share in 2026. Although the revenue estimates have not really changed 10x Genomics'future looks a little different to the past, with a favorable reduction in the loss per share forecasts in particular.

These new estimates led to the consensus price target rising 19% to US$49.54, with lower forecast losses suggesting things could be looking up for 10x Genomics. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on 10x Genomics, with the most bullish analyst valuing it at US$60.00 and the most bearish at US$40.00 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that 10x Genomics' revenue growth is expected to slow, with the forecast 0.8% annualised growth rate until the end of 2026 being well below the historical 7.5% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 6.9% per year. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than 10x Genomics.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple 10x Genomics analysts - going out to 2028, and you can see them free on our platform here.

You still need to take note of risks, for example - 10x Genomics has 2 warning signs we think you should be aware of.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.